Literature DB >> 22773602

Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia.

Candice Bereal-Williams, Roberto F Machado, Vicki McGowan, Amy Chi, Christian J Hunter, Gregory J Kato, Lori Hunter, Carole K Dalby, Kristine Partovi Hauser, Anitaben Tailor, Richard O Cannon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22773602      PMCID： PMC3487454          DOI： 10.3324/haematol.2011.054957

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.

Authors:  U Laufs; S Wassmann; S Hilgers; N Ribaudo; M Böhm; G Nickenig
Journal:  Am J Cardiol       Date:  2001-12-01       Impact factor: 2.778

2.  Pulmonary hypertension and NO in sickle cell.

Authors:  Mark T Gladwin; Robyn J Barst; Oswaldo L Castro; Victor R Gordeuk; Cheryl A Hillery; Gregory J Kato; Daniel B Kim-Shapiro; Roberto Machado; Claudia R Morris; Martin H Steinberg; Elliott P Vichinsky
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

3.  Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.

Authors:  Gregory J Kato; Sabrina Martyr; William C Blackwelder; James S Nichols; Wynona A Coles; Lori A Hunter; Marie-Luise Brennan; Stanley L Hazen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

4.  Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients.

Authors:  F Perticone; R Ceravolo; R Maio; C Cloro; M Candigliota; A Scozzafava; A Mongiardo; P Mastroroberto; M Chello; P L Mattioli
Journal:  Atherosclerosis       Date:  2000-10       Impact factor: 5.162

5.  Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation.

Authors:  L Belhassen; G Pelle; S Sediame; D Bachir; C Carville; C Bucherer; C Lacombe; F Galacteros; S Adnot
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

6.  Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse.

Authors:  D K Kaul; X D Liu; M E Fabry; R L Nagel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-06       Impact factor: 4.733

7.  Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease.

Authors:  K A Nath; V Shah; J J Haggard; A J Croatt; L A Smith; R P Hebbel; Z S Katusic
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-12       Impact factor: 3.619

8.  A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.

Authors:  Carolyn Hoppe; Frans Kuypers; Sandra Larkin; Ward Hagar; Elliott Vichinsky; Lori Styles
Journal:  Br J Haematol       Date:  2011-04-08       Impact factor: 6.998

9.  Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin.

Authors:  Anna Solovey; Rahn Kollander; Arun Shet; Liming C Milbauer; Stephana Choong; Angela Panoskaltsis-Mortari; Bruce R Blazar; Robert J Kelm; Robert P Hebbel
Journal:  Blood       Date:  2004-04-08       Impact factor: 22.113

10.  Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels.

Authors:  Robert T Eberhardt; Lillian McMahon; Stephen J Duffy; Martin H Steinberg; Susan P Perrine; Joseph Loscalzo; Jay D Coffman; Joseph A Vita
Journal:  Am J Hematol       Date:  2003-10       Impact factor: 10.047
View more
  10 in total

1.  Featured Article: Alterations of lecithin cholesterol acyltransferase activity and apolipoprotein A-I functionality in human sickle blood.

Authors:  Eric Soupene; Mark S Borja; Mauricio Borda; Sandra K Larkin; Frans A Kuypers
Journal:  Exp Biol Med (Maywood)       Date:  2016-06-27

2.  Atorvastatin inhibits hyperglycemia-induced expression of osteopontin in the diabetic rat kidney via the p38 MAPK pathway.

Authors:  Li Zuo; Yong Du; Man Lu; Junling Gao; Ruolei Hu; Sumei Zhang; Yi Wang; Huaqing Zhu; Qing Zhou; Wei Wei; Yuan Wang
Journal:  Mol Biol Rep       Date:  2014-01-23       Impact factor: 2.316

Review 3.  2015 Clinical trials update in sickle cell anemia.

Authors:  Natasha Archer; Frédéric Galacteros; Carlo Brugnara
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

Review 4.  New insights into the pathophysiology and development of novel therapies for sickle cell disease.

Authors:  Scott Moerdler; Deepa Manwani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.

Authors:  Carolyn Hoppe; Eufemia Jacob; Lori Styles; Frans Kuypers; Sandra Larkin; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2017-03-28       Impact factor: 6.998

Review 6.  Evolving treatment paradigms in sickle cell disease.

Authors:  Ramasamy Jagadeeswaran; Angela Rivers
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Iron, inflammation, and early death in adults with sickle cell disease.

Authors:  Eduard J van Beers; Yanqin Yang; Nalini Raghavachari; Xin Tian; Darlene T Allen; James S Nichols; Laurel Mendelsohn; Sergei Nekhai; Victor R Gordeuk; James G Taylor; Gregory J Kato
Journal:  Circ Res       Date:  2014-11-06       Impact factor: 17.367

8.  Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels.

Authors:  Heather M Scoffone; Megan Krajewski; Suzana Zorca; Candice Bereal-Williams; Patricia Littel; Catherine Seamon; Laurel Mendelsohn; Eleni Footman; Nadine Abi-Jaoudeh; Vandana Sachdev; Roberto F Machado; Michael Cuttica; Robert Shamburek; Richard O Cannon; Alan Remaley; Caterina P Minniti; Gregory J Kato
Journal:  Am J Cardiol       Date:  2013-09-13       Impact factor: 2.778

9.  Circulating endothelial progenitor cells in adults with sickle cell disease.

Authors:  Maria Rodrigo; Laurel Mendelsohn; Candice Bereal-Williams; Lori Hunter; Carole K Dalby; Vicki McGowan; Christian J Hunter; Roberto F Machado; J Philip McCoy; Richard O Cannon; Gregory J Kato
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

Review 10.  Emerging disease-modifying therapies for sickle cell disease.

Authors:  Marcus A Carden; Jane Little
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.